{"title":"Multifunctional MeHA hydrogel for living materials delivery with enhanced cartilage regeneration.","authors":"Qunchao Chen, Lang Bai, Guoyang Wan, Yuefeng Hao, Xing Yang, Hongtao Zhang","doi":"10.3389/fbioe.2025.1545773","DOIUrl":null,"url":null,"abstract":"<p><p>Particulated juvenile articular cartilage (PJAC) has emerged as a promising living material for articular defect treatment. However, the fragile nature of PJAC hinders its wide clinical application. Here, inspired by the chemical composition and hierarchical structure of natural cartilage, we developed a novel hydrogel carrier system for PJAC delivery. Our carrier system, MeHA@J@DM, utilized methacrylated hyaluronic acid (MeHA) to incorporate PJAC and coated it with a polymerized mixture of dopamine methacrylamide (DMA) and 2-methylacryloyloxyethyl phosphorylcholine (MPC), forming an adhesive lubricant, p(DMA-MPC). MeHA@J@DM exhibited excellent performance for PJAC protection with enhanced cell viability, bioactivity, and lubrication properties. We evaluated the effectiveness of MeHA@J@DM in cartilage cell migration, where juvenile cartilage showed greater efficiency and remodeling abilities. <i>In vivo</i> rabbit cartilage defect models demonstrated superior cartilage regeneration with the MeHA@J@DM hydrogel. Our findings suggest that MeHA@J@DM has translational potential for PJAC implantation to enhance cartilage regeneration and benefit patients with articular cartilage lesions.</p>","PeriodicalId":12444,"journal":{"name":"Frontiers in Bioengineering and Biotechnology","volume":"13 ","pages":"1545773"},"PeriodicalIF":4.3000,"publicationDate":"2025-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12162624/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Bioengineering and Biotechnology","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.3389/fbioe.2025.1545773","RegionNum":3,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Particulated juvenile articular cartilage (PJAC) has emerged as a promising living material for articular defect treatment. However, the fragile nature of PJAC hinders its wide clinical application. Here, inspired by the chemical composition and hierarchical structure of natural cartilage, we developed a novel hydrogel carrier system for PJAC delivery. Our carrier system, MeHA@J@DM, utilized methacrylated hyaluronic acid (MeHA) to incorporate PJAC and coated it with a polymerized mixture of dopamine methacrylamide (DMA) and 2-methylacryloyloxyethyl phosphorylcholine (MPC), forming an adhesive lubricant, p(DMA-MPC). MeHA@J@DM exhibited excellent performance for PJAC protection with enhanced cell viability, bioactivity, and lubrication properties. We evaluated the effectiveness of MeHA@J@DM in cartilage cell migration, where juvenile cartilage showed greater efficiency and remodeling abilities. In vivo rabbit cartilage defect models demonstrated superior cartilage regeneration with the MeHA@J@DM hydrogel. Our findings suggest that MeHA@J@DM has translational potential for PJAC implantation to enhance cartilage regeneration and benefit patients with articular cartilage lesions.
期刊介绍：
The translation of new discoveries in medicine to clinical routine has never been easy. During the second half of the last century, thanks to the progress in chemistry, biochemistry and pharmacology, we have seen the development and the application of a large number of drugs and devices aimed at the treatment of symptoms, blocking unwanted pathways and, in the case of infectious diseases, fighting the micro-organisms responsible. However, we are facing, today, a dramatic change in the therapeutic approach to pathologies and diseases. Indeed, the challenge of the present and the next decade is to fully restore the physiological status of the diseased organism and to completely regenerate tissue and organs when they are so seriously affected that treatments cannot be limited to the repression of symptoms or to the repair of damage. This is being made possible thanks to the major developments made in basic cell and molecular biology, including stem cell science, growth factor delivery, gene isolation and transfection, the advances in bioengineering and nanotechnology, including development of new biomaterials, biofabrication technologies and use of bioreactors, and the big improvements in diagnostic tools and imaging of cells, tissues and organs.
In today`s world, an enhancement of communication between multidisciplinary experts, together with the promotion of joint projects and close collaborations among scientists, engineers, industry people, regulatory agencies and physicians are absolute requirements for the success of any attempt to develop and clinically apply a new biological therapy or an innovative device involving the collective use of biomaterials, cells and/or bioactive molecules. “Frontiers in Bioengineering and Biotechnology” aspires to be a forum for all people involved in the process by bridging the gap too often existing between a discovery in the basic sciences and its clinical application.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
